Metastatic Urothelial Cancer Active Not Recruiting Phase 2 Trials for Enfortumab vedotin (DB13007)

DBCOND0066157 (Metastatic Urothelial Cancer)Active Not Recruiting2 IdentifierTitlePurposeDrugs
NCT04995419A Study to Evaluate Enfortumab Vedotin (ASG-22CE) in Chinese Participants With Locally Advanced or Metastatic Urothelial Cancer Who Previously Received Platinum-containing Chemotherapy and Programmed Cell Death Protein-1 ( PD 1) / (Programmed Death Ligand-1 (PD-L1) Inhibitor TherapyTreatment